Understanding Acute Kidney Injury in Children: The Role of Serum Cystatin C in Intensive Care

Аннотация

Acute Kidney Injury (AKI) is a critical condition often encountered in pediatric intensive care units (PICUs), characterized by a rapid decline in kidney function. Early diagnosis and intervention are crucial to improving outcomes in these vulnerable patients. Serum Cystatin C (CysC), a promising biomarker, has emerged as a potential diagnostic tool for detecting AKI in children. Unlike traditional markers such as serum creatinine, CysC is less influenced by age, gender, and muscle mass, making it a more reliable indicator of kidney function in pediatric populations. This review aims to explore the role of Serum Cystatin C in the early detection, diagnosis, and monitoring of AKI in children within the PICU setting. The potential advantages, limitations, and clinical implications of CysC as a biomarker are discussed, along with recent research findings highlighting its utility in pediatric AKI. Ultimately, understanding the role of CysC could lead to improved outcomes by enabling timely interventions and better management strategies for pediatric patients at risk of AKI. Keywords: Acute Kidney Injury, Pediatric Intensive Care Unit, Serum Cystatin C, Biomarker, Kidney Function, Early Diagnosis, Pediatric Nephrology, Critical Care, Renal Biomarkers, Kidney Injury Detection, Pediatric AKI, Serum Creatinine, Pediatric Medicine. reliable marker for kidney function as it is less Introduction: Acute Kidney Injury (AKI) remains a influenced by factors such as age, sex, and muscle mass significant cause of morbidity and mortality in critically compared to creatinine. ill pediatric patients, particularly in intensive care settings. It is a complex condition defined by a rapid Recent studies have highlighted the potential decline in kidney function, leading to disturbances in advantages of serum Cystatin C in the early diagnosis fluid, electrolyte balance, and waste product and monitoring of AKI in pediatric patients, especially accumulation. Early identification and timely in critical care settings. CysC offers several benefits, intervention are crucial for improving outcomes in including its ability to detect subtle changes in kidney children affected by AKI. In pediatric intensive care function before traditional markers become elevated. units (PICUs), where patients are often critically ill and Additionally, its use could lead to more accurate present with multiple comorbidities, the challenge of prognostication, enabling clinicians to initiate timely diagnosing AKI becomes even more complex. interventions to prevent further renal damage. Traditionally, serum creatinine has been used as the This review aims to delve into the role of serum primary biomarker for diagnosing and monitoring Cystatin C in the diagnosis and management of AKI in kidney function. However, its reliability in pediatric pediatric patients within intensive care units. By populations, especially in those with low muscle mass, exploring its utility, limitations, and clinical is limited. This limitation has prompted researchers to implications, we hope to provide a comprehensive explore alternative biomarkers that can provide earlier understanding of how this biomarker can potentially and more accurate detection of AKI in children. One enhance the care of critically ill children at risk for AKI. such promising biomarker is serum Cystatin C (CysC), a Through this, we seek to highlight the importance of low-molecular-weight protein produced by all CysC as a diagnostic tool that may improve outcomes nucleated cells. CysC has shown potential as a more and inform better management strategies in pediatric International Journal of Medical Sciences And Clinical Research 1 https://theusajournals.com/index.php/ijmscr International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265) AKI. Outcomes: The study must have reported on the diagnostic accuracy of CysC, including sensitivity,